Key Takeaways
- Rick Scott and Sen. Gillibrand (D-NY) touted Clear Labels Act requiring country-of-origin labels after HELP Committee advanced it unanimously in July.
- Kurt Orlofski (CEO, PAI Pharma) urged Congress to require labels, prioritize FDA reviews for domestic makers, and incentivize US purchasing.
- Sen. Gillibrand (D-NY) pressed Mihir Torsekar (Senior Economist, Coalition for a Prosperous America) on pre-announced foreign inspections enabling foreign undercutting.
- Rick Scott and Sen. Gillibrand (D-NY) agreed on reshoring generics, backing labels, domestic procurement, and 180-day exclusivity reform to counter China and India.
- Congress must finalize CMS domestic reimbursement, permanent FDA priority review, and higher foreign fees to prevent catastrophic shortages and deaths.
Same-day access
Unlocks publicly on September 30, 2026
Every transcript becomes free to read one week after the hearing. Subscribe to read this one today.
Get instant accessPlans from $100/mo
Billed monthly · cancel anytime
Not ready to subscribe?
Get the free morning digest. It covers yesterday’s hearings and lists transcripts as they unlock, including this one.
